# Hansoh Pharma's HS-20122 Posts 61.3% Response Rate in EGFR-Mutant Lung Cancer Phase 1

> Hansoh Pharma presented Phase 1 data for HS-20122 at ESMO 2026, showing a 61.3% response rate in EGFR-mutant lung cancer after TKI failure.

- Published: 2026-10-25T01:40:07+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-25/hansoh-pharma-hs-20122-phase-1-results
- Source: [The future of trading](https://capital.com/en-int/news/hansoh-pharma-reports-61-3-response-rate-for-hs-20122-in-phase)

## Key takeaways

- Hansoh Pharma presented Phase 1 results for HS-20122 at ESMO in Madrid on October 24, 2026, showing a 61.3% response rate in EGFR-mutant lung cancer after TKI failure.
- HS-20122 showed antitumor activity across advanced solid tumors, with most treatment-related adverse events mild to moderate.
- Hansoh Pharma and Roche entered a partnership and licensing deal worth over $15 billion covering antibody-drug conjugate programs, with a $400 million upfront payment to Hansoh.

Hansoh Pharma presented Phase 1 results for HS-20122 at ESMO in Madrid on October 24, 2026, showing a 61.3% response rate in EGFR-mutant lung cancer after TKI failure. [The future of trading](https://capital.com/en-int/news/hansoh-pharma-reports-61-3-response-rate-for-hs-20122-in-phase) reported the results. The drug showed antitumor activity across advanced solid tumors, with manageable safety.

## Hansoh's HS-20122 Phase 1 Data at ESMO

Hansoh Pharmaceutical Group Co. Ltd. Is a Shanghai-based drugmaker whose pipeline spans oncology, metabolic disease and antibody-drug conjugates. The company [published the original content](http://www.hansoh.cn/en) behind the ESMO presentation.

The Phase 1 trial evaluated HS-20122 in patients with advanced solid tumors, with particular activity in EGFR-mutated lung cancer following failure of EGFR-targeted therapy. Safety was manageable, and most treatment-related adverse events were mild to moderate. Serious events primarily involved blood abnormalities. The findings support further development in multiple solid tumors, including EGFR-mutated lung cancer.

## Roche Deal and Earlier Hansoh Readouts

Hansoh Pharmaceutical and Roche entered a partnership and licensing deal worth over $15 billion covering antibody-drug conjugate programs, EIN Presswire reported in October 2026. Hansoh receives an upfront $400 million and a first anniversary payment of $110 million, with further milestone payments.

Hansoh Pharma presented Phase III data for its dual-biased GLP-1/GIP agonist Olatorepatide at EASD 2026, showing mean weight loss of 19.3% at week 48 in the 15 mg group versus 2.7% in placebo, PR Newswire reported in October 2026. On September 2, 2026, Hansoh Pharmaceutical announced that its injectable HS-20093 (Risvutatug Rezetecan) for adult small cell lung cancer patients who failed platinum-based therapy was accepted for marketing authorization by China's National Medical Products Administration, Jiemian reported.

## Other ESMO 2026 Readouts

Johnson & Johnson announced new PROTEUS substudy results showing apalutamide plus androgen deprivation therapy before and after surgery reduced recurrence or death risk by 62% versus surgery alone in high-risk prostate cancer, [PR Newswire reported](https://www.prnewswire.com/news-releases/johnson--johnson-announces-erleada-apalutamide-treatment-before-and-after-surgery-reduces-risk-of-recurrence-or-death-by-62-versus-surgery-alone-in-high-risk-prostate-cancer-302918654.html) on October 24, 2026.

Quanta Therapeutics presented positive clinical data for QTX3034 combined with cetuximab and/or chemotherapy in KRAS G12D-mutant colorectal cancer at ESMO 2026, showing a 25% overall response rate and 75% disease control, [GlobeNewswire reported](https://www.globenewswire.com/news-release/2026/10/24/3387679/0/en/quanta-presents-positive-clinical-combination-data-in-kras-g12d-mutant-crc-at-esmo-and-highlights-pan-kras-progress.html). CatalYm presented final results from its Phase 2 GDFATHER-NEO trial at ESMO 2026, showing visugromab plus nivolumab improved pathologic complete response (33% vs 8%) in neoadjuvant bladder cancer, [FinancialContent Business Page reported](https://www.financialcontent.com/article/bizwire-2026-10-24-catalym-presents-phase-2-data-showing-visugromab-substantially-enhances-the-clinical-benefit-of-pd-1-inhibition-in-neoadjuvant-bladder-cancer-at-esmo-2026).

## What Comes Next for HS-20122

The findings support further development of HS-20122 in multiple solid tumors, including EGFR-mutated lung cancer. Quanta Therapeutics' QTX6255, a pan-KRAS inhibitor, is advancing toward an IND filing in 4Q26, GlobeNewswire reported.

## Companies in this story

- Hansoh Pharma · website: http://www.hansoh.cn/en

---
News for Agent · https://newsforagent.com/llms.txt